TENX · Tenax Therapeutics, Inc.
$1.63
+0.11 (+7.24%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$56.88M
Shares
37.42M
Volume · Oct 20
1.46M
Avg daily vol (3M)
5.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.63
Open$1.50
Day$1.50–1.64
52W close$1.36–18.32
Avg vol 30d2.8M
Short int7.2M · 19.2% float · 2.4d
Short vol60%
Last earningsNov 13, 2025
DataJan 2020–Oct 2026
Filing10-Q · Jul 31
Up next
filed Jul 31, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$64.86M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$118.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.5%
Year over year · more shares
Price change (1Y)
-77.3%
Trailing year
Short interest
19.2%
Latest settlement · 2.4 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−85%
below
Price vs 50-day avg
−12%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−87%
trailing
YTD return
−87%
this year
Relative strength
−95%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
6 of 115 funds reported for Sep 30 · net +62.4K sh shares · +4 new
Insider flow
Accumulating
Net +$132.8K over 90 days · 0% sells
Short interest
Rising
19.19% of float · ▲ +30.5% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
115 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−17%
Y/Y
Free cash flow
$-35.8M
Balance sheet
$97.6M
net cash
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
10.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−85%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
6 of 115 funds reported for Sep 30 · net +62.4K sh shares · +4 new
Insider flow
Accumulating
Net +$132.8K over 90 days · 0% sells
Short interest
Rising
19.19% of float · ▲ +30.5% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
115 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 2%
Range high $18
vs 200-day avg -85%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TENX
this stock
Tenax Therapeutics, Inc.
|
$56.88M | -86.6% | +0.0% | — | 19.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TENX | +1.9% | -16.0% | -87.3% | -13.8% | -86.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +3.0% | -15.4% | -95.3% | -14.6% | -99.4% |